Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.44 |
| ▸ | MAOB | P27338 | 6/20 | 0.44 |
| ▸ | PRF1 | P14222 | 4/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2588544 | 0.93 | MAOA (0.44) | MAOAMAOBPRF1PDE4DPDE4A | |
| SCHEMBL7716256 | 0.92 | MAOA (0.43) | MAOAMAOBPRF1PDE4DPTGS2 | |
| SCHEMBL2590026 | 0.91 | MAOA (0.46) | MAOAMAOBPRF1PDE4DPTGS2 | |
| SCHEMBL2592339 | 0.90 | MAOA (0.44) | MAOAMAOBPRF1PDE4DPDE4A | |
| SCHEMBL7711333 | 0.89 | MAOA (0.44) | MAOAMAOBPRF1PDE4DPTGS2 | |
| SCHEMBL2589783 | 0.87 | MAOA (0.46) | MAOAMAOBPRF1PDE4DPTGS2 | |
| SCHEMBL7712590 | 0.85 | MAOA (0.43) | MAOAMAOBPRF1PDE4DPDE4A | |
| SCHEMBL7711917 | 0.85 | MAOA (0.45) | MAOAMAOBPRF1PTGS2ACHE | |
| SCHEMBL2584393 | 0.84 | PDE4A (0.37) | PDE4DPDE4APDE4BPDE4CPTGS2 | |
| SCHEMBL2584975 | 0.83 | PRF1 (0.43) | MAOAMAOBPRF1PDE4DPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563770-B1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2016-03-23 | — | — | EP | disclosed |
| US-9051290-B2 | Biaryl phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-06-09 | — | — | US | disclosed |
| US-9051290-B2 | Biaryl phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2015-06-09 | — | — | US | disclosed |
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-03-07 | — | — | US | disclosed |
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059853-A1 | BIARYL PHOSPHODIESTERASE INHIBITORS | PDE3B, PDE3A, PDE4A | MAOA 191/4885MAOB 223/4885PRF1 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.